# Study Of Palbociclib (PD-0332991) In Renal Impairment

> **NCT02085538** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** palbociclib
- **DRUG:** palbociclib
- **DRUG:** palbociclib
- **DRUG:** palbociclib

## Key facts

- **NCT ID:** NCT02085538
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085538, "Study Of Palbociclib (PD-0332991) In Renal Impairment". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02085538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*